Your browser doesn't support javascript.
Incidence of immediate allergic reactions to mRNA COVID-19 vaccines in adults with drug allergies and other allergic disorders.
Markovic, Ivan; Bozan, Marina; Perkovic, Tomislav; Pausek, Katarina; Nedeljkovic, Vanja; Perkovic, Marina; Kelava, Tomislav; Artukovic, Marinko; Stipic Markovic, Asja.
  • Markovic I; Special Hospital for Pulmonary Diseases, Zagreb, Croatia.
  • Bozan M; Special Hospital for Pulmonary Diseases, Zagreb, Croatia.
  • Perkovic T; Special Hospital for Pulmonary Diseases, Zagreb, Croatia.
  • Pausek K; Special Hospital for Pulmonary Diseases, Zagreb, Croatia.
  • Nedeljkovic V; Special Hospital for Pulmonary Diseases, Zagreb, Croatia.
  • Perkovic M; Special Hospital for Pulmonary Diseases, Zagreb, Croatia.
  • Kelava T; Department of Physiology and Immunology, University of Zagreb, School of Medicine, Zagreb, Croatia.
  • Artukovic M; Special Hospital for Pulmonary Diseases, Zagreb, Croatia.
  • Stipic Markovic A; Special Hospital for Pulmonary Diseases, Zagreb, Croatia.
Medicine (Baltimore) ; 101(30): e29571, 2022 Jul 29.
Article in English | MEDLINE | ID: covidwho-1967936
ABSTRACT
Concerns have been raised about allergic reactions to messenger ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccines. A history of allergic reactions, including anaphylaxis to drugs, has been frequently reported in individuals with anaphylaxis to mRNA vaccines. To estimate the rate of immediate allergic reactions in patients with a history of drug allergy or other allergic disorders. We included adult patients who had received at least 1 dose of an mRNA COVID-19 vaccine at the Special Hospital for Pulmonary Diseases between March 1, 2021, and October 1, 2021, and who reported a history of drug allergy or other allergic diseases (asthma, allergic rhinitis, atopic dermatitis, food or insect venom allergy, mastocytosis, idiopathic anaphylaxis, acute or chronic urticaria, and/or angioedema). Immediate allergic reactions, including anaphylaxis, occurring within 4 hours of vaccination were recorded. Six immediate allergic reactions were noted in the cohort of 1679 patients (0.36%). One patient experienced anaphylaxis (0.06%), which resolved after epinephrine administration, and the other reactions were mild and easily treatable. Most patients with a history of allergies can safely receive an mRNA COVID-19 vaccine, providing adequate observation periods and preparedness to recognize and treat anaphylaxis.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Dermatitis, Atopic / Drug Hypersensitivity / COVID-19 Vaccines / COVID-19 / Anaphylaxis Type of study: Cohort study / Observational study / Prognostic study Topics: Long Covid / Vaccines Limits: Adult / Humans Language: English Journal: Medicine (Baltimore) Year: 2022 Document Type: Article Affiliation country: MD.0000000000029571

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Dermatitis, Atopic / Drug Hypersensitivity / COVID-19 Vaccines / COVID-19 / Anaphylaxis Type of study: Cohort study / Observational study / Prognostic study Topics: Long Covid / Vaccines Limits: Adult / Humans Language: English Journal: Medicine (Baltimore) Year: 2022 Document Type: Article Affiliation country: MD.0000000000029571